GADODIAMIDE vs IOPAMIDOL

Compare GADODIAMIDE (OMNISCAN) and IOPAMIDOL (iopamidol) — clinical data, side effects, and patient experiences.

GADODIAMIDE

OMNISCAN · Diagnostic Agent

How it works

12.2 Pharmacodynamics In magnetic resonance imaging, visualization of normal and pathologic tissue depends in part on variations in the radiofrequency signal intensity. These varia...

Approved for

spine

and associated tissues ( 1.1 ) Facilitate the visualization of lesions with abnormal vascularity within the thoracic

abdominal

pelvic cavities

IntravenousTablet

IOPAMIDOL

iopamidol · Diagnostic Agent

How it works

Diagnostic Agent agent

Approved for

INDICATIONS AND USAGE Iopamidol Injection is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar

thoracic

cervical

total columnar)

IntrathecalTablet

Quick Comparison

GADODIAMIDEIOPAMIDOL

Drug Class

Diagnostic Agent

Route

Intravenous

Intrathecal

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

GADODIAMIDE

Anxiety

1-10%

Joint Pain

0.1-1%

Peripheral Edema

0.1-1%

Rash

0.1-1%

Weakness

0.1-1%

IOPAMIDOL

Shortness of Breath

1-10%

Itching

1-10%

Nausea

1-10%

Vomiting

1-10%

Fever

0.1-1%

Cough

0.1-1%

FDA Warnings

GADODIAMIDE

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Anaphylactoid and other serious hypersensitivity reactions including fatal reactions have occurred particularly in patients with history of allergy or drug reactions
1 Risk Associated with Intrathecal Use Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures
2 Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs
The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing

IOPAMIDOL

WARNINGS The need for myelographic examination should be carefully evaluated
If frankly bloody cerebrospinal fluid is observed, the possible benefits of a myelographic examination should be considered in terms of risk to the patient
Inadvertent intracranial entry of a large or concentrated bolus of the contrast medium, which increases the risk of neurotoxicity, can be prevented by careful patient management

Clinical Trial Data

No head-to-head clinical studies found for GADODIAMIDE vs IOPAMIDOL.

GADODIAMIDE vs IOPAMIDOL: What You Should Know

Key Differences

Both GADODIAMIDE and IOPAMIDOL belong to the Diagnostic Agent class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. GADODIAMIDE is administered via Intravenous, whereas IOPAMIDOL uses Intrathecal. Route of administration can affect onset of action and patient adherence.

Safety Considerations

GADODIAMIDE carries 4 FDA warnings. IOPAMIDOL carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

GADOBUTROL vs IOPAMIDOL→GADOBUTROL vs GADODIAMIDE→AIR 90% CARBON DIOXIDE 10% vs IOPAMIDOL→AIR 90% CARBON DIOXIDE 10% vs GADODIAMIDE→CARBON DIOXIDE vs IOPAMIDOL→IODIXANOL vs IOPAMIDOL→

Loading comparison data...

GADODIAMIDE vs IOPAMIDOL

Compare GADODIAMIDE (OMNISCAN) and IOPAMIDOL (iopamidol) — clinical data, side effects, and patient experiences.

GADODIAMIDE

OMNISCAN · Diagnostic Agent

How it works

12.2 Pharmacodynamics In magnetic resonance imaging, visualization of normal and pathologic tissue depends in part on variations in the radiofrequency signal intensity. These varia...

Approved for

spine

and associated tissues ( 1.1 ) Facilitate the visualization of lesions with abnormal vascularity within the thoracic

abdominal

pelvic cavities

IntravenousTablet

IOPAMIDOL

iopamidol · Diagnostic Agent

How it works

Diagnostic Agent agent

Approved for

INDICATIONS AND USAGE Iopamidol Injection is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar

thoracic

cervical

total columnar)

IntrathecalTablet

Quick Comparison

GADODIAMIDEIOPAMIDOL

Drug Class

Diagnostic Agent

Route

Intravenous

Intrathecal

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

GADODIAMIDE

Anxiety

1-10%

Joint Pain

0.1-1%

Peripheral Edema

0.1-1%

Rash

0.1-1%

Weakness

0.1-1%

IOPAMIDOL

Shortness of Breath

1-10%

Itching

1-10%

Nausea

1-10%

Vomiting

1-10%

Fever

0.1-1%

Cough

0.1-1%

FDA Warnings

GADODIAMIDE

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Anaphylactoid and other serious hypersensitivity reactions including fatal reactions have occurred particularly in patients with history of allergy or drug reactions
1 Risk Associated with Intrathecal Use Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures
2 Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs
The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing

IOPAMIDOL

WARNINGS The need for myelographic examination should be carefully evaluated
If frankly bloody cerebrospinal fluid is observed, the possible benefits of a myelographic examination should be considered in terms of risk to the patient
Inadvertent intracranial entry of a large or concentrated bolus of the contrast medium, which increases the risk of neurotoxicity, can be prevented by careful patient management

Clinical Trial Data

No head-to-head clinical studies found for GADODIAMIDE vs IOPAMIDOL.

GADODIAMIDE vs IOPAMIDOL: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.